Acoramidis Alternatives Compared
| Acoramidis | Tafamidis | Vyndaqel (tafamidis) |
|
|---|
| Acoramidis | Tafamidis | Vyndaqel (tafamidis) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Cardiomyopathy of Transthyretin-Mediated Amyloidosis. Acoramidis may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Cardiomyopathy of Transthyretin-Mediated Amyloidosis, Hereditary Amyloidosis, Transthyretin-Related Amyloidosis. Tafamidis may also be used for purposes not listed in this medication guide. View more |
Prescription only
Prescribed for Cardiomyopathy of Transthyretin-Mediated Amyloidosis, Transthyretin-Related Amyloidosis. Vyndaqel may also be used for purposes not listed in this medication guide. |
Related suggestions Cardiomyopathy of Transthyretin-Mediated Amyloidosis
|
|||||||
| More about Acoramidis | More about Tafamidis | More about Vyndaqel (tafamidis) | ||||||||
| Ratings & Reviews | ||||||||||
|
Be the first to share your experience with this drug. |
Tafamidis has an average rating of 7.7 out of 10 from a total of 15 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 0% reported a negative effect. |
Vyndaqel has an average rating of 7.0 out of 10 from a total of 2 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
|
View all Acoramidis side effects |
View all Tafamidis side effects |
View all Vyndaqel side effects |
||||||||
| Drug Class | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Vyndaqel prices |
||||||||
| Dosage Forms | ||||||||||
|
N/A |
N/A |
|
||||||||
| Brand Names | ||||||||||
| Attruby | Vyndamax, Vyndaqel | Other tafamidis brands include: Vyndamax | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
|
6 hours |
59 hours |
59 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 23 drugs are known to interact with Acoramidis:
|
A total of 32 drugs are known to interact with Tafamidis:
|
A total of 32 drugs are known to interact with Vyndaqel:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
November 22, 2024 |
May 03, 2019 |
May 03, 2019 |
||||||||
| WADA Class View classifications | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient Resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.